Loading
NASDAQHealthcareBiotechnology
Latest quote
$152.05
−$3.60 · -2.31%
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest quote
$152.05
−$3.60 · -2.31%
After-hours
$152
−$0.05 · -0.03%
Oct 8, 7:53 PM ET
Regular session · ET · Market data may be delayed.
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Day range
Current $152.05
52-week range
Current $152.05
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
62
Undervalued
Sentiment
45
Mixed
Risk
55
Elevated Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Day range
Current $152.05
52-week range
Current $152.05
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 376.57M USD | 312.97M USD | 245.11M USD | 203.57M USD | 132.33M USD |
| Cost of goods sold | 185.57M USD | 179.63M USD | 155.38M USD | 119.33M USD | 80.62M USD |
| Gross profit | 191M USD | 133.35M USD | 89.73M USD | 84.24M USD | 51.71M USD |
| Research and development | 80.29M USD | 90.85M USD | 106.89M USD | 120.31M USD | 69.07M USD |
| Selling, general, and administrative | 246.98M USD | 218.4M USD | 189.74M USD | 212.95M USD | 135.9M USD |
| Operating expenses | 327.26M USD | 354.18M USD | 306.89M USD | 319.01M USD | 204.44M USD |
| Interest income | 11.36M USD | 15.34M USD | 14.37M USD | 3.06M USD | 435K USD |
| Interest expense | — | 29K USD | 5K USD | 80K USD | 367K USD |
| Depreciation and amortization | 24.85M USD | 31.43M USD | 29.31M USD | 16.51M USD | 9.75M USD |
| Operating income | −136.26M USD | −220.83M USD | −217.16M USD | −234.78M USD | −152.73M USD |
| Net income | −77.67M USD | −208.73M USD | −204.62M USD | −217.86M USD | −152.1M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$145.2
4.51% downsideFunds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK381.87M3.45%5.56B USD0.75%$87.60-0.79%
Vanguard Morningstar Total Stock Market ETFVTI276.54M0.01%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM270.61M0.35%77.7B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap ETFVB200.04M0.11%185.3B USD0.03%$287.63+0.23%
State Street SPDR S&P Biotech ETFXBI188.33M1.87%10.11B USD0.35%$149.29-0.63%
ARK Genomic Revolution ETFARKG182.51M8.65%1.56B USD0.75%$49.29-1.70%
Vanguard Morningstar Small-Cap Growth ETFVBK114.8M0.25%44.7B USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF105.62M0.11%95.4B USD0.05%$233.13-0.15%ARK Innovation ETFARKKVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
